Immune cell therapy for relapsed plasma cell cancers
Part of Cancer clinical trials.
This study is testing a new type of cell therapy (called CAR-T) that uses your own immune cells to attack the cancer cells in plasma cell tumors. It is designed for patients with multiple myeloma, plasma cell leukemia, plasmacytoma, or amyloidosis that has returned or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of blood cancer called plasma cell neoplasm (like multiple myeloma or amyloidosis) that has come back or not responded to treatment.
- Your cancer cells must have a marker called CD19 or BCMA (these are proteins on the cell surface).
- You must be between 18 and 75 years old.
- You must have tried at least 3 previous treatments (or at least 2 for amyloidosis) and they did not work or stopped working.
- Your overall health should be reasonably good – you should be able to take care of yourself and your heart, lungs, kidneys, and liver should be functioning well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to attack cancer cells that have certain markers (CD19 or BCMA). It is for people with blood cancers like multiple myeloma or certain lymphomas that have not responded to multiple prior treatments. The goal is to see if this treatment can help when other options have failed.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack cancer cells in patients with multiple myeloma, plasmacytoma, plasma cell leukemia, or light chain amyloidosis that have not responded well to previous treatments. The goal is to see if this approach can help patients whose cancers have become resistant to standard medicines.
This trial is testing a new type of cell therapy that uses your own immune cells (called CAR-T cells) to fight your cancer. The cells are modified to attack two specific targets on your cancer cells (BCMA and GPRC5D) to potentially improve treatment response.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Hear when a new Relapsed or Refractory Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.